Anticancer agent 164
CML-IN-1 (compound 7) is a potent anticancer agent. CML-IN-1 displays very good induced-apoptosis effect for human chronic myeloid leukemia (CML) cell line K562. CML-IN-1 exerts its effect via a significantly reduced protein phosphorylation of PI3K/Akt signal pathway. CML-IN-1 (compound 4) also inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2235393-30-1
- Formel: C21H23F3N8O2S2
- Molecular Weight:540.58
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle MEK Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
5.52 μM
Compound: compound 4
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
|
[PMID: 37857146] |
| K562 | IC50 |
0.038 μM
Compound: 7
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by real time live-cell imaging technique
Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by real time live-cell imaging technique
|
[PMID: 31097376] |
CML-IN-1 (compound 7) exhibits the least cellular toxicity and better biological activity in cellular assays (K562, IC50: 0.038 μM)[1].
CML-IN-1 (compound 4) significantly inhibits HCT116 cell proliferation with IC50 values of 8.04 ± 0.94 µM after 48 h and 5.52 ± 0.42 µM after 72 h, respectively[2].
CML-IN-1 (compound 4) inhibits colony formation, migration, and invasion of HCT116 cells in a dose-dependent manner, as well as inducing cell apoptosis and arresting the cell cycle in the G2/M phase[2].
CML-IN-1 (compound 4) inhibits the activation of the MEK/ERK signaling in HCT116 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 2235393-30-1
-
Molecular Weight 540.58
-
Formel C21H23F3N8O2S2
-
SMILES
O=C(NC1=CC=C(C(F)(F)F)C=C1)NC2=NN=C(SC3=NC=NC(NCCCN4CCOCC4)=C3)S2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Li W, et al. Design and synthesis of novel 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1,3,4-thiadiazol- 2-yl)urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway. Bioorg Med Chem Lett. 2019 Jul 15;29(14):1831-1835. [Content Brief]
[2]. Li W, et al. A novel 4-(1,3,4-thiadiazole-2-ylthio)pyrimidine derivative inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer. Acta Pharm. 2023 Sep 14;73(3):489-502. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Anticancer agent 164 Related Classifications
HY-128634 Related Classifications
Powered by Bioz